MIJ821

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Depressive Disorder, Treatment-ResistantMajor Depressive Disorder

Phase 1

An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain

CompletedNCT05666687

Novartis PharmaceuticalsMajor Depressive Disorder

Start: 2023-01-11End: 2023-11-07Updated: 2024-04-01

Phase 2

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

CompletedNCT03756129

Novartis PharmaceuticalsDepressive Disorder, Treatment-Resistant

Start: 2019-02-08End: 2020-03-23Updated: 2021-10-08

Related Papers

Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression

The Journal of Clinical Psychiatry2025-08-06

Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study

European Psychiatry2021-04-0113 citations